

**UWL REPOSITORY**  
**repository.uwl.ac.uk**

Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms

Eldehnaa, W M, Taghourb, M S, Al-Warhi, T, Nocentini, A, Elbadawi, M M, Mahdy, H A, Abdelrahman, M A, Alotaibi, O J, Aljaeed, N, Elimam, D M, Afarinkia, Kamyar ORCID logo ORCID: <https://orcid.org/0000-0003-2819-4364>, Abdel-Aziz, H A and Supuran, C T (2022) Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 37 (1). pp. 531-541.

<http://dx.doi.org/10.1080/14756366.2021.2024528>

This is the Published Version of the final output.

UWL repository link: <https://repository.uwl.ac.uk/id/eprint/12826/>

**Alternative formats:** If you require this document in an alternative format, please contact: [open.research@uwl.ac.uk](mailto:open.research@uwl.ac.uk)

**Copyright:** Creative Commons: Attribution 4.0

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.



**Take down policy:** If you believe that this document breaches copyright, please contact us at [open.research@uwl.ac.uk](mailto:open.research@uwl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

**Rights Retention Statement:**

RESEARCH PAPER



## Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms

Wagdy M. Eldehna<sup>a</sup>, Mohammed S. Taghour<sup>b</sup>, Tarfah Al-Warhi<sup>c</sup>, Alessio Nocentini<sup>d</sup> , Mostafa M. Elbadawi<sup>a</sup>, Hazem A. Mahdy<sup>b</sup>, Mohamed A. Abdelrahman<sup>e</sup>, Ohoud J. Alotaibi<sup>c</sup>, Nada Aljaeed<sup>c</sup>, Diaaeldin M. Elimam<sup>f,g</sup>, Kamyar Afarinkia<sup>h</sup>, Hatem A. Abdel-Aziz<sup>i</sup> and Claudiu T. Supuran<sup>d</sup> 

<sup>a</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt; <sup>b</sup>Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt; <sup>c</sup>Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia; <sup>d</sup>Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy; <sup>e</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt; <sup>f</sup>Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt; <sup>g</sup>School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom; <sup>h</sup>Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom; <sup>i</sup>Department of Applied Organic Chemistry, National Research Center, Giza, Egypt

### ABSTRACT

Different 2,4-thiazolidinedione-tethered coumarins **5a–b**, **10a–n** and **11a–d** were synthesised and evaluated for their inhibitory action against the cancer-associated *h*CA IX and XII, as well as the physiologically dominant *h*CA I and II to explore their selectivity. Un-substituted phenyl-bearing coumarins **10a**, **10h**, and 2-thienyl/furyl-bearing coumarins **11a–c** exhibited the best *h*CA IX ( $K_i$ s between 0.48 and 0.93  $\mu$ M) and *h*CA XII ( $K_i$ s between 0.44 and 1.1  $\mu$ M) inhibitory actions. Interestingly, none of the coumarins had any inhibitory effect on the off-target *h*CA I and II isoforms. The sub-micromolar compounds from the biochemical assay, coumarins **10a**, **10h** and **11a–c**, were assessed in an *in vitro* antiproliferative assay, and then the most potent antiproliferative agent **11a** was tested to explore its impact on the cell cycle phases and apoptosis in MCF-7 breast cancer cells to provide more insights into the anticancer activity of these compounds.

### ARTICLE HISTORY

Received 10 December 2021  
Accepted 27 December 2021

### KEYWORDS

Carbonic anhydrase inhibitors; 3-acetylcoumarin; apoptosis induction; anticancer agents; hypoxic tumours





## 1. Introduction


Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes found in all living organisms and are responsible for the catalysis of the biologically crucial reversible hydration of carbon dioxide to bicarbonate and proton. This is a simple but pivotal physiological reaction which is essential for normal and pathological processes such as CO<sub>2</sub> and pH homeostasis, respiration, gluconeogenesis, calcification, bone resorption, fluid secretion and tumorigenesis [1,2]. CAs are grouped into different families, amongst them  $\alpha$ -CAs which are present in all vertebrates and are further sub-classified into fifteen isoforms (herein referred to as human CAs or *h*CA) that differ by molecular features, expression levels, kinetic properties and cellular distribution in the different tissues [3]. Of note, only twelve *h*CA are catalytically active (I–IV, VA, VB, VI, VII, IX, XII–XIV) with an active site containing three histidine residues in a triple coordination with a zinc ion [4]. Regarding the subcellular distribution of the catalytically active *h*CA, they can be categorised into different subsets: cytosolic (I, II, III, VII and XIII), trans-membrane (IV, IX, XII, and XIV), mitochondrial (VA and VB), while VI is secreted in saliva and milk [5]. The over-expressed levels and/or dysfunctions of *h*CA can lead to many disorders, hence CA inhibitors (CAIs) are utilised for the treatment

of glaucoma (targeting *h*CA II, IV and XII), edoema (targeting *h*CA II, IV and XIV), mental disorders (targeting *h*CA II, VII and XIV) and obesity (targeting *h*CA VA and VB) [4,6,7].

It should be stressed that the trans-membranous *h*CA IX and XII are hypoxia-induced tumours-associated isozymes and over-expressed in most cancer cells compared to the normal ones [8]. While the overexpressed *h*CA IX isozyme is mainly linked to cancer poor prognosis and limited to hypoxic tumours, *h*CA XII can be found in some normal tissues like kidney and colon alongside the hypoxic tumours [9,10]. Interestingly, the tumour growth, angiogenesis, proliferation and metastasis are attributed to the over-expressed levels of *h*CA IX and XII suggesting a strategy for targeting of such enzymes as a new approach in cancer chemotherapy [8,11]. In this context, selective inhibition of the tumour-associated *h*CA IX and XII isozymes over the other isoforms, particularly the most prevalent cytosolic *h*CA I and II is highly desirable and will result in cancer treatment with fewer side effects [12].


In view of this, intensive efforts are being conducted for the development of *h*CA IX/XII selective inhibitors as a validated approach for cancer treatment [13–15]. *h*CA IX and XII can be inhibited by different strategies such as coordination to the zinc

**CONTACT** Wagdy M. Eldehna  [wagdy2000@gmail.com](mailto:wagdy2000@gmail.com)  Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt; Claudiu T. Supuran  [claudiu.supuran@unifi.it](mailto:claudiu.supuran@unifi.it)  Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy

 Supplemental data for this article can be accessed [here](#).

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 1.** Some reported coumarins acting as selective CA IX/XII inhibitors.

ion situated in the catalytic active site. Molecules in this class are exemplified by sulfonamide-derived *h*CAIs and their bioisosters. In addition, the occlusion of the catalytic active cleft is explored and this approach has been explored using coumarins as a newly discovered *h*CAIs class [16,17].

Coumarin **I** is a naturally-derived, privileged heterocyclic scaffold and molecules containing it show numerous biological properties such as inhibition of CK2, EGFR and PI3K-AKT-mTOR signalling. Moreover, coumarins are known to have anticoagulation, monoamine oxidase inhibition, anti-infective, antioxidant, anti-inflammatory and anticancer activities [14,18–20]. Coumarins are recently discovered as a novel class of *h*CAIs with inhibitory mechanism different from the sulfonamide-based inhibitors. Coumarins act as prodrug undergoing hydrolysis by the esterase activity of CA to yield 2-hydroxycinnamic acid derivative **II** which can bind to the active site cleft occluding its entrance, **Figure 1** [15,21]. Since coumarins binding sites are the most heterologous region of the active site between all CAs isoforms, it is not surprising that these chemotypes displaying very high selectivity for specific CAs isoforms. Furthermore, the chemical simplicity of coumarins permits the facile incorporation of diverse substituents, leading to generation of a large number of derivatives with interesting biological profiles [22]. Consequently, many ongoing efforts have focussed on developing novel coumarin derivatives as selective *h*CAIs IX/XII inhibitors that could be used for cancer therapy. For instance, diverse coumarins **III–X** have been reported as selective *h*CAIs IX/XII inhibitors with nanomolar  $K_i$ , **Figure 1** [8,10,13,17,21–24].

Inspired by these findings, we prepared a series of 2,4-thiazolidinedione-tethered coumarins, compounds **5a–b**, **10a–n** and **11a–d**, and evaluated their inhibitory action against the cancer-associated *h*CAIs IX and XII, and selectivity over inhibition of the physiologically dominant *h*CAIs I and II to explore their selectivity in order to the cancer-related isoforms. Moreover, the efficient *h*CAIs IX/XII inhibitors **10a**, **10h** and **11a–c** were subjected to

*in vitro* antiproliferative assay under hypoxic conditions and most potent antiproliferative agent **11a** was tested to explore its impact on the cell cycle phases and apoptosis in MCF-7 breast cancer cells furnishing more insights on the anticancer activity of such compounds.

## 2. Experimental

### 2.1. Chemistry

#### 2.1.1. General

The NMR spectra were recorded by Bruker 400 MHz spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$  spectra were run at 400 and 100 MHz, respectively, in deuterated dimethylsulphoxide ( $\text{DMSO-}d_6$ ) or deuterated trifluoroacetic acid. All coupling constant ( $J$ ) values are given in hertz. IR spectra were recorded with a Bruker FT-IR spectrophotometer. Reaction courses and product mixtures were routinely monitored by thin layer chromatography (TLC) on silica gel precoated  $\text{F}_{254}$  Merck plates. Unless otherwise mentioned, all reagents and solvents are commercially available and have been used without further purification. Compounds **2** and **3** are previously reported [25,26].

#### 2.1.2. General procedures for synthesis of 3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione derivatives (**5a–b**)

To a stirred solution of 3-(2-bromoacetyl)-2H-chromen-2-one **3a** (0.27 g, 1.0 mmol) or 6-bromo-3-(2-bromoacetyl)-2H-chromen-2-one **3b** (0.34 g, 1.0 mmol) in DMF (7 ml), thiazolidine-2,4-dione **4** (0.12 g, 1.0 mmol), anhydrous  $\text{K}_2\text{CO}_3$  (0.28 g, 2.0 mmol) and KI (cat.) were added. The reaction mixture was heated on a water bath for 8 h, then was poured over crushed ice. The precipitate was filtered, dried, and crystallized from hot ethanol to give the corresponding key intermediates **5a–b**, respectively.

**2.1.2.1. 3-(2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 5a.** Yellow crystals (yield, 80%); m. p. = 180–181 °C (reported: 161–163 °C [27]); <sup>1</sup>H NMR (400 MHz, Trifluoroacetic acid-d<sub>1</sub>): δ 8.79 (s, 1H, H-4 coumarin moiety), 8.01 (d, *J* = 8.0 Hz, 1H, H-5 coumarin moiety), 7.81 (t, *J* = 7.2 Hz, 1H, H-7 coumarin moiety), 7.51 (d, *J* = 8.0 Hz, 1H, H-8 coumarin moiety), 7.46 (t, *J* = 7.6 Hz, 1H, H-6 coumarin moiety), 5.13 (s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-), 4.10 (s, 2H, CH<sub>2</sub>, -S-CH<sub>2</sub>-CO-); <sup>13</sup>C NMR (101 MHz, Trifluoroacetic acid-d<sub>1</sub>) δ 189.47, 172.32, 159.16, 155.25, 149.25, 135.73, 131.67, 125.63, 122.60, 118.53, 116.75, 50.43 (-N-CH<sub>2</sub>-), 34.54 (-S-CH<sub>2</sub>-); Anal. Calcd. for C<sub>14</sub>H<sub>9</sub>NO<sub>5</sub>S (303.29): C, 55.44; H, 2.99; N, 4.62; Found: C, 55.68; H, 3.01; N, 4.56.

**2.1.2.2. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)thiazolidine-2,4-dione 5b.** Yellow crystals (yield, 75%); m. p. = 239–241 °C (reported: 171–173 °C [27]); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.59 (s, 1H, H-4 coumarin), 8.20 (s, 1H, H-5 coumarin), 7.88 (d, *J* = 8.8 Hz, 1H, H-7 coumarin), 7.44 (d, *J* = 8.8 Hz, 1H, H-8 coumarin), 5.14 (s, 2H, CH<sub>2</sub>), 4.11 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 195.41, 158.46, 154.08, 146.09, 137.04, 132.10, 125.85, 120.52, 118.86, 116.82, 60.22 (-N-CH<sub>2</sub>-), 30.49 (-S-CH<sub>2</sub>-); Anal. Calcd. for C<sub>14</sub>H<sub>8</sub>BrNO<sub>5</sub>S (382.18): C, 44.00; H, 2.11; N, 3.66; Found: C, 43.85; H, 2.12; N, 3.69.

### 2.1.3. General procedures for preparation of the intermediates 8a–g and 9a–b

To a solution of thiazolidine-2,4-dione **4** (0.12 g, 1 mmol) in glacial acetic acid (5 ml), anhydrous sodium acetate (0.08 g, 1 mmol) and the appropriate aldehyde derivative (**6a–g** and **7a–b**) were added. The resulting reaction mixture was allowed to stir under reflux for 3h. The precipitated solid was collected by filtration while hot, washed with cold ethanol and water, and dried to afford intermediates **8a–g** and **9a–b**.

### 2.1.4. General procedures for preparation of coumarins 10a–n and 11a–d

The appropriate benzylidene derivative **8a–g** (2 mmol) was added to a hot stirred mixture of 3-(bromoacetyl)coumarin derivatives **3a–b** (2 mmol), K<sub>2</sub>CO<sub>3</sub> (0.55 g, 4 mmol), KI (2 mmol) in DMF (8 ml), then the resulting mixture was stirred under reflux for 8h. The formed precipitates were collected by filtration, washed with water, dried and recrystallized from DMF/water to yield the final target coumarin-based CALs **10a–n** and **11a–d**.

**2.1.4.1. 5-Benzylidene-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10a.** Grey crystals (yield, 70%); m. p. = 249–251 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.17 (s, 1H, ArH), 8.27 (s, 1H, -CH=), 8.01–7.97 (m, 2H, ArH), 7.70–7.61 (m, 7H, ArH), 5.64 (s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 173.27, 172.54, 168.52, 168.28, 153.27, 139.52, 139.52, 137.19, 132.00, 131.79, 131.19, 130.47, 129.01, 126.36, 118.57, 116.70, 115.75, 54.32 (-N-CH<sub>2</sub>-); Anal. Calcd. for C<sub>21</sub>H<sub>13</sub>NO<sub>5</sub>S (391.40): C, 64.44; H, 3.35; N, 3.58; Found: C, 64.71; H, 3.37; N, 3.52 [28].

**2.1.4.2. 5-(4-Methylbenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10b.** Yellow crystals (yield, 85%); m. p. = 227–229 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.61 (s, 1H, ArH), 8.04 (d, *J* = 8.0 Hz, 1H, ArH), 7.79 (t, *J* = 7.6 Hz, 1H, H-7 ArH), 7.72 (s, 1H, -CH=), 7.51 (d, *J* = 8.0 Hz, 1H, ArH), 7.47 (d, *J* = 8.0 Hz, 2H, ArH), 7.48 (t, *J* = 7.6 Hz, 1H, ArH), 7.33 (d, *J* = 8.0 Hz, 2H, ArH), 5.13

(s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-), 2.41 (s, 3H, CH<sub>3</sub>); Anal. Calcd. for C<sub>22</sub>H<sub>15</sub>NO<sub>5</sub>S (405.42): C, 65.18; H, 3.73; N, 3.45; Found: C, 64.95; H, 3.76; N, 3.51.

**2.1.4.3. 5-(4-Methoxybenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10c.** Yellow crystals (yield, 85%); m. p. = 257–259 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.16 (s, 1H, ArH), 8.24 (s, 1H, -CH=), 8.00–7.96 (m, 2H, ArH), 7.71 (d, *J* = 8.8 Hz, 2H, ArH), 7.65–7.61 (m, 2H, ArH), 7.23 (d, *J* = 8.8 Hz, 2H, ArH), 5.63 (s, 2H, CH<sub>2</sub>), 4.10 (s, 3H, OCH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 172.54, 168.38, 162.43, 162.00, 161.56, 161.13, 153.19, 139.03, 137.03, 132.98, 131.07, 126.39, 126.00, 118.52, 118.05, 116.05, 115.71, 112.90, 110.08, 54.90 (OCH<sub>3</sub>), 51.47 (-N-CH<sub>2</sub>-); Anal. Calcd. for C<sub>22</sub>H<sub>15</sub>NO<sub>6</sub>S (421.42): C, 62.70; H, 3.59; N, 3.32; Found: 62.88; H, 3.62; N, 3.26 [28].

**2.1.4.4. 5-(2,5-Dimethoxybenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10d.** Grey crystals (yield, 82%); m. p. = 238–240 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.87 (s, 1H, ArH), 8.28 (s, 1H, -CH=), 7.76–7.73 (m, 2H, ArH), 7.42–7.39 (m, 2H, ArH), 7.08–6.93 (m, 3H, ArH), 5.36 (s, 2H, CH<sub>2</sub>), 3.84 (s, 3H, OCH<sub>3</sub>), 3.82 (s, 3H, OCH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, DMSO) δ 206.65, 189.23, 167.42, 165.61, 159.17, 153.66, 153.59, 152.95, 149.34, 135.63, 131.61, 129.04, 122.59, 122.52, 122.23, 121.89, 117.80, 116.65, 113.64, 56.31 (OCH<sub>3</sub>), 55.73 (OCH<sub>3</sub>), 50.67 (-N-CH<sub>2</sub>-); Anal. Calcd. for C<sub>23</sub>H<sub>17</sub>NO<sub>7</sub>S (451.45): C, 61.19; H, 3.80; N, 3.10; Found: 60.94; H, 3.83; N, 3.14.

**2.1.4.5. 5-(4-Nitrobenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10e.** Yellow crystals (yield, 77%); m. p. = 263–265 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.84 (s, 1H, ArH), 8.36 (d, *J* = 8.8 Hz, 2H, ArH), 8.13 (s, 1H, -CH=), 8.00 (d, *J* = 8.4 Hz, 1H, ArH), 7.93 (d, *J* = 8.4 Hz, 2H, ArH), 7.86–7.79 (m, 2H, ArH), 7.44 (t, *J* = 8.0 Hz, 1H, ArH), 5.24 (s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-); <sup>13</sup>C NMR (101 MHz, DMSO) δ 189.33, 165.32, 159.25, 155.31, 149.42, 148.23, 139.55, 135.84, 131.73, 131.65, 131.27, 128.47, 125.66, 124.72, 122.55, 118.57, 116.79, 50.99 (-N-CH<sub>2</sub>-); Anal. Calcd. for C<sub>21</sub>H<sub>12</sub>N<sub>2</sub>O<sub>7</sub>S (436.39): C, 57.80; H, 2.77; N, 6.42; Found: C, 58.03; H, 2.75; N, 6.49.

**2.1.4.6. 5-(2-Chlorobenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10f.** Yellow crystals (yield, 77%); m. p. = 208–211 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.84 (s, 1H, ArH), 8.06 (s, 1H, -CH=), 8.01 (d, *J* = 8.0 Hz, 1H, ArH), 7.84 (d, *J* = 8.0 Hz, 1H, ArH), 7.79 (d, *J* = 8.4 Hz, 1H, ArH), 7.71 (d, *J* = 8.0 Hz, 1H, ArH), 7.66–7.59 (m, 2H, ArH), 7.51 (d, *J* = 8.4 Hz, 1H, ArH), 7.44 (t, *J* = 8.4 Hz, 1H, ArH), 5.23 (s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-); <sup>13</sup>C NMR (101 MHz, DMSO) δ 189.39, 167.21, 165.20, 159.24, 149.43, 135.84, 134.17, 133.07, 132.88, 132.04, 131.74, 129.69, 129.24, 125.79, 125.67, 125.19, 122.57, 118.56, 116.79, 55.39 (-N-CH<sub>2</sub>-); Anal. Calcd. for C<sub>21</sub>H<sub>12</sub>ClNO<sub>5</sub>S (425.84): C, 59.23; H, 2.84; N, 3.29; Found: C, 59.43; H, 2.82; N, 3.25.

**2.1.4.7. 5-(2-Bromobenzylidene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 10g.** Yellow crystals (yield, 82%); m. p. = 230–232 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.15 (s, 1H, ArH), 8.64 (s, 1H, -CH=), 8.00–7.97 (m, 2H, ArH), 7.74–7.72 (m, 1H, ArH), 7.66–7.63 (m, 3H, ArH), 7.53–7.56 (m, 2H, ArH), 5.65 (s, 2H, CH<sub>2</sub>, -N-CH<sub>2</sub>-CO-); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 190.49, 172.12, 167.88, 163.26, 162.48, 162.04, 161.61, 161.17, 155.14, 136.60, 130.43, 121.61, 119.96, 118.49, 118.05, 115.68, 112.86,

110.05, 50.72 (–N–CH<sub>2</sub>–); Anal. Calcd. for C<sub>21</sub>H<sub>12</sub>BrNO<sub>5</sub>S (470.29): C, 53.63; H, 2.57; N, 2.98; Found: C, 53.81; H, 2.58; N, 3.01

**2.1.4.8. 5-Benzylidene-3-(2-(6-bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)thiazolidine-2,4-dione 10h.** Yellow crystals (yield, 78%); m. p. = 252–254 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H, ArH), 8.21 (d, *J* = 2.4 Hz, 1H, ArH), 7.87 (d, *J* = 7.6 Hz, 1H, ArH), 7.78 (s, 1H, –CH=), 7.43–7.61 (m, 6H, ArH), 5.14 (s, 2H, CH<sub>2</sub>, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR (101 MHz, DMSO) δ 168.61, 168.30, 146.11, 137.06, 134.29, 133.60, 133.42, 133.01, 131.94, 130.81, 130.45, 129.78, 125.88, 124.43, 120.54, 118.88, 117.04, 116.83, 50.83(–N–CH<sub>2</sub>–); Anal. Calcd. for C<sub>21</sub>H<sub>12</sub>BrNO<sub>5</sub>S (470.29): C, 53.63; H, 2.57; N, 2.98; Found: C, 53.78; H, 2.56; N, 3.00.

**2.1.4.9. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(4-methylbenzylidene)thiazolidine-2,4-dione 10i.** Yellow crystals (yield, 86%); m. p. = 224–225 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H, ArH), 8.20 (s, 1H, ArH), 7.86 (d, *J* = 8.8 Hz, 1H, ArH), 7.78 (s, 1H, –CH=), 7.47 (d, *J* = 8.0 Hz, 2H, ArH), 7.42 (d, *J* = 8.8 Hz, 1H, ArH), 7.33 (d, *J* = 8.0 Hz, 2H, ArH), 5.13 (s, 2H, –N–CH<sub>2</sub>–CO–), 2.35 (s, 3H, CH<sub>3</sub>); Anal. Calcd. for C<sub>22</sub>H<sub>14</sub>BrNO<sub>5</sub>S (484.32): C, 54.56; H, 2.91; N, 2.89; Found: C, 54.75; H, 2.89; N, 2.90.

**2.1.4.10. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione 10j.** Grey crystals (yield, 72%); m. p. = 245–247 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H, ArH), 8.21 (d, *J* = 2.4 Hz, 1H, ArH), 7.87 (d, *J* = 8.0 Hz, 1H, ArH), 7.73 (s, 1H, –CH=), 7.54 (d, *J* = 8.8 Hz, 2H, ArH), 7.43 (d, *J* = 8.0 Hz, 1H, ArH), 7.08 (d, *J* = 8.8 Hz, 2H, ArH), 5.20 (s, 2H, –N–CH<sub>2</sub>–CO–), 3.82 (s, 3H, OCH<sub>3</sub>); Anal. Calcd. for C<sub>22</sub>H<sub>14</sub>BrNO<sub>6</sub>S (500.32): C, 52.81; H, 2.82; N, 2.80; Found: C, 53.04; H, 2.83; N, 2.80.

**2.1.4.11. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(2,5-dimethoxybenzylidene)thiazolidine-2,4-dione 10k.** Yellow crystals (yield, 78%); m. p. = 204–206 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.59 (s, 1H, ArH), 8.21 (d, *J* = 2.4 Hz, 1H, ArH), 7.90 (s, 1H, –CH=), 7.87 (d, *J* = 8.0 Hz, 1H, ArH), 7.42 (d, *J* = 8.0 Hz, 1H, ArH), 7.08–7.07 (m, 2H, ArH), 6.91 (d, *J* = 8.0 Hz, 1H, ArH), 5.19 (s, 2H, –N–CH<sub>2</sub>–CO–), 3.83 (s, 3H, OCH<sub>3</sub>), 3.75 (s, 3H, OCH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 162.46, 162.02, 161.74, 161.59, 161.15, 154.65, 152.12, 134.08, 122.06, 120.32, 118.49, 115.74, 115.68, 113.18, 112.86, 110.05, 56.32, 55.38. Anal. Calcd. for C<sub>23</sub>H<sub>16</sub>BrNO<sub>7</sub>S (530.35): C, 52.09; H, 3.04; N, 2.64; Found: C, 51.89; H, 3.07; N, 2.63.

**2.1.4.12. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(4-nitrobenzylidene)thiazolidine-2,4-dione 10l.** Yellow crystals (yield, 82%); m. p. = 229–231 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.77 (s, 1H, ArH), 8.38 (s, 1H, ArH), 8.32 (d, *J* = 8.8 Hz, 2H, ArH), 7.93 (dd, *J* = 8.8, 2.0 Hz, 1H, ArH), 7.88 (s, 1H, –CH=), 7.84 (d, *J* = 8.8 Hz, 2H, ArH), 7.49 (d, *J* = 8.8 Hz, 1H, ArH), 5.13 (s, 2H, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR (101 MHz, DMSO) δ 189.24, 168.05, 167.94, 166.89, 165.28, 158.81, 154.31, 148.23, 147.88, 139.95, 139.52, 131.65, 131.35, 129.28, 128.90, 125.63, 124.73, 123.59, 120.40, 117.06, 50.98. Anal. Calcd. for C<sub>21</sub>H<sub>11</sub>BrN<sub>2</sub>O<sub>7</sub>S (515.29): C, 48.95; H, 2.15; N, 5.44; Found: C, 49.11; H, 2.14; N, 5.48.

**2.1.4.13. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(2-chlorobenzylidene)thiazolidine-2,4-dione 10m.** Yellow crystals (yield, 77%); m. p. = 192–194 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.65 (s, 1H, ArH), 8.12 (s, 1H, ArH), 8.05 (d, *J* = 8.8 Hz, 1H, ArH), 7.75–7.51 (m, 6H, ArH), 5.64 (s, 2H, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR

(101 MHz, TFA-deuterated) δ 162.52, 162.09, 161.66, 161.22, 151.67, 139.52, 138.48, 135.27, 133.00, 132.66, 132.42, 130.36, 128.68, 127.03, 119.33, 118.51, 115.69, 112.88, 110.07. Anal. Calcd. for C<sub>21</sub>H<sub>11</sub>BrClNO<sub>5</sub>S (504.74): C, 49.97; H, 2.20; N, 2.78; Found: C, 50.13; H, 2.21; N, 2.80.

**2.1.4.14. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(2-bromobenzylidene)thiazolidine-2,4-dione 10n.** Yellow crystals (yield, 72%); m. p. = 208–210 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.61 (s, 1H, ArH), 8.22 (s, 1H, ArH), 7.87 (d, *J* = 8.8 Hz, 1H, ArH), 7.79 (s, 1H, –CH=), 7.51–7.59 (m, 3H, ArH), 7.43 (d, *J* = 8.8 Hz, 1H, ArH), 7.34 (t, *J* = 8.0 Hz, 1H, ArH), 5.14 (s, 2H, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR (101 MHz, DMSO) δ 207.46, 158.94, 158.47, 154.43, 154.09, 146.11, 137.06, 134.21, 134.16, 133.92, 133.01, 131.75, 129.88, 129.61, 129.39, 129.23, 128.93, 120.54, 118.88, 116.83, 30.50. Anal. Calcd. for C<sub>21</sub>H<sub>11</sub>Br<sub>2</sub>NO<sub>5</sub>S (549.19): C, 45.93; H, 2.02; N, 2.55; Found: C, 46.09; H, 2.03; N, 2.53.


### 2.1.5. General procedures for preparation of target coumarins 11a–d

5-(Thiophen-2-ylmethylene)thiazolidine-2,4-dione **7a** (15 mmol) and/or 5-((5-methylfuran-2-yl)methylene)thiazolidine-2,4-dione **7b** (15 mmol) was added to a hot stirred solution of 3-(bromoacetyl) coumarin derivatives **3a,b** (15 mmol) in DMF (10 ml), K<sub>2</sub>CO<sub>3</sub> (15 mmol), KI (15 mmol), then the resulting mixture was stirred under reflux for 8h. The precipitates were collected by filtration, washed with water, dried and recrystallized from hexane/ethanol to yield the final target compounds **11a–d**.

**2.1.5.1. 3-(2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)-5-(thiophen-2-ylmethylene)thiazolidine-2,4-dione 11a.** Yellow crystals (yield, 83%); m. p. = 250–251 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.13 (s, 1H, ArH), 8.44 (s, 1H, –CH=), 7.97–7.91 (m, 3H, ArH), 7.68–7.61 (m, 3H, ArH), 7.33 (t, *J* = 4.8 Hz, 1H, ArH), 5.62 (s, 2H, CH<sub>2</sub>, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 190.74, 162.45, 162.02, 161.58, 161.14, 153.33, 137.00, 136.28, 134.41, 131.79, 131.08, 128.63, 126.38, 119.93, 118.48, 115.67, 112.85, 110.04, 50.74. Anal. Calcd. for C<sub>19</sub>H<sub>11</sub>NO<sub>5</sub>S<sub>2</sub> (397.42): C, 57.42; H, 2.79; N, 3.52; Found: C, 57.26; H, 2.78; N, 3.55.

**2.1.5.2. 5-((5-Methylfuran-2-yl)methylene)-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione 11b.** Yellow crystals (yield, 70%); m. p. = 227–229 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.12 (s, 1H, ArH), 7.96–7.90 (m, 3H, –CH= and ArH), 7.62–7.60 (m, 2H, ArH), 7.09 (d, *J* = 4.0 Hz, 1H, ArH), 6.40 (d, *J* = 4.0 Hz, 1H, ArH), 5.60 (s, 2H, CH<sub>2</sub>, –N–CH<sub>2</sub>–CO–), 2.54 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, TFA-deuterated) δ 162.45, 162.02, 161.57, 161.14, 153.32, 147.87, 136.96, 131.05, 126.35, 124.21, 118.47, 118.02, 116.58, 115.66, 112.84, 110.55, 110.03, 110.03, 50.50, 12.05; Anal. Calcd. for C<sub>20</sub>H<sub>13</sub>NO<sub>6</sub>S (395.39): C, 60.76; H, 3.31; N, 3.54; Found: C, 60.92; H, 3.34; N, 3.51.

**2.1.5.3. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-(thiophen-2-ylmethylene)thiazolidine-2,4-dione 11c.** Yellow crystals (yield, 76%); m. p. = 255–257 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H, ArH), 8.27 (d, *J* = 2.4 Hz, 1H, ArH), 8.04 (s, 1H, –CH=), 7.99 (d, *J* = 5.2 Hz, 1H, ArH), 7.93 (dd, *J* = 8.8, 2.4 Hz, 1H, ArH), 7.66 (d, *J* = 8.0 Hz, 1H, ArH), 7.48 (d, *J* = 3.6 Hz, 1H, ArH), 7.27 (t, *J* = 3.6 Hz, 1H, ArH), 5.20 (s, 2H, –N–CH<sub>2</sub>–CO–); <sup>13</sup>C NMR (101 MHz, DMSO) δ 189.40, 167.97, 167.84, 165.35, 158.79, 147.90, 146.11, 137.84, 137.41, 136.00, 134.92, 133.42, 129.39, 127.63, 125.40,



**Scheme 1.** Reagents and conditions: (i) Abs. Ethanol, piperidine, reflux, 2 h; (ii) bromine 99%, glacial acetic acid, r.t., 6 h; (iii) anhydrous DMF, potassium carbonate, potassium iodide, heating on a water bath, 8 h.

121.86, 120.42, 117.04, 50.93. Anal. Calcd. for  $C_{19}H_{10}BrNO_5S_2$  (476.32): C, 47.91; H, 2.12; N, 2.94; Found: C, 47.79; H, 2.13; N, 2.96.

**2.1.5.4. 3-(2-(6-Bromo-2-oxo-2H-chromen-3-yl)-2-oxoethyl)-5-((5-methylfuran-2-yl)methylene)thiazolidine-2,4-dione 11d.** Yellow crystals (yield, 79%); m. p. = 236–238 °C;  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.60 (s, 1H, ArH), 8.22 (d,  $J=2.4$  Hz, 1H, ArH), 7.99 (dd,  $J=8.8, 2.4$  Hz, 1H, ArH), 7.74 (s, 1H,  $-CH=$ ), 7.43 (d,  $J=8.8$  Hz, 1H, ArH), 6.99 (d,  $J=4.0$  Hz, 1H, ArH), 6.39 (d,  $J=4.0$  Hz, 1H, ArH), 5.17 (s, 2H,  $-N-CH_2-CO-$ ), 2.38 (s, 3H,  $CH_3$ );  $^{13}C$  NMR (101 MHz, DMSO)  $\delta$  189.51, 169.37, 167.80, 157.74, 148.41, 147.87, 146.11, 137.80, 137.06, 133.40, 133.01, 122.00, 120.69, 119.25, 119.05, 118.80, 111.03, 110.72, 50.58, 14.22. Anal. Calcd. for  $C_{20}H_{12}BrNO_6S$  (474.28): C, 50.65; H, 2.55; N, 2.95; Found: C, 50.52; H, 2.57; N, 2.98.

## 2.2. Biological evaluation

The experimental procedures for CA stopped-flow [29–31], MTT cell viability [32,33], cell cycle [34] and Annexin V-FITC/PI [35] assays are included in the Supporting Information.

## 3. Results and discussion

### 3.1. Chemistry

The proposed synthetic routes to obtain the target coumarins are depicted in Scheme 1 and Scheme 2. First, condensation of 2-hydroxybenzaldehydes **1a–b** with ethyl 3-oxobutanoate in refluxing absolute ethanol in the presence of a few drops of piperidine yielded 3-acetylcoumarins **2a–b**. These were subjected to bromination via reaction with  $Br_2$  in glacial acetic acid to yield the key 3-(bromoacetyl)coumarin intermediates **3a–b**, which were subsequently treated with thiazolidine-2,4-dione **4** in refluxing DMF using anhydrous  $K_2CO_3$  as base and KI as a nucleophilic catalyst to afford 3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione derivatives **5a–b** (Scheme 1).

Synthesis of compounds **8a–g** and **9a–b** (Scheme 2) was achieved via refluxing of thiazolidine-2,4-dione **4** with benzaldehyde derivatives **6a–g** and **7a–b** in glacial acetic acid and anhydrous sodium acetate. Treatment of **8a–g** and **9a–b** with the key intermediates **3a–b** in refluxing DMF using anhydrous  $K_2CO_3$  and

KI furnished the corresponding final targets 5-benzylidene-3-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)thiazolidine-2,4-dione **10a–n** and **11a–d**, respectively. Proposed structures for the synthesised coumarins were in agreement with their various spectroscopic and analytical data.


### 3.2. Carbonic anhydrase inhibition

The inhibitory influence of all the synthesised coumarins **5a–b**, **10a–n** and **11a–d** was investigated against *hCA* I, II IX and XII isoforms using a stopped flow  $CO_2$  hydrase assay and a well-known *hCA*I, acetazolamide (**AAZ**) as control [36]. From the resulting inhibition constants ( $K_i$ ) shown in Table 1, certain structure activity relationship (SAR) can be inferred.

Coumarins **5a–b**, **10a–n** and **11a–d** are devoid of significant inhibition towards the off-target ubiquitous *hCA* I and the physiologically dominant *hCA* II ( $K_i$ s > 100  $\mu$ M) isoforms, Table 1. In contrast, these coumarins inhibited the cancer-related *hCA* IX with inhibition constants spanning a range between 0.12 and 18.2  $\mu$ M, (Table 1). Regarding the unsubstituted thiazolidinedione-bearing coumarins **5a–b**, the absence of substitution at 6-position of coumarin scaffold furnished the most effective *hCA* IX inhibitor in this work displaying  $K_i$  of 0.12  $\mu$ M, whereas, the 6-bromination decreased the *hCA* IX inhibitory power 2-folds ( $K_i = 0.24$   $\mu$ M).

In the context of *hCA* IX inhibition constants of the benzylidene counterparts **10a–n**, it was found that 6-unsubstituted coumarins **10a–g** showed effective inhibition ( $K_i$ s ranged from 0.82 to 12.3  $\mu$ M) compared to the 6-bromo analogues **10h–n** ( $K_i$ s spanned between 0.93 and 18.2  $\mu$ M). In the term of coumarins with the benzylidene moiety, **10a–g**, it is worth stressing that appending an unsubstituted aryl ring to the thiazolidinedione moiety **10a** provided the most effective *hCA* IX inhibitor within this series ( $K_i = 0.82$   $\mu$ M). Indeed, the incorporation of *ortho*-chloro or *ortho*-bromophenyl (**10f** and **10g**, respectively) decreased the inhibition constants to low micromolar values ( $K_i$ s = 2.2 and 2.3  $\mu$ M, respectively). Regrettably, the remaining phenyl substitution pattern were similarly poorer *hCA* IX inhibitors with  $K_i$ s equalling 4.3  $\mu$ M (*p*-methyl, **10b**), 5.8  $\mu$ M (*p*-methoxy, **10c**), 8.4  $\mu$ M (2,5-dimethoxy, **10d**), 12.3  $\mu$ M (*p*-nitro, **10e**).

In a similar fashion, the appending of unsubstituted aryl ring to the 6-bromocoumarins **10h–n** produced the most potent *hCA*



**Scheme 2.** Reagents and conditions: (i) glacial acetic acid, reflux 3 h; (ii) DMF, potassium carbonate, potassium iodide, reflux 8 h.

IX inhibitor within this series (**10h**;  $K_i = 0.93 \mu\text{M}$ ), whereas *ortho* chlorination or bromination reduced the inhibition constants to low micromolar values (**10m** and **10n**;  $K_i$ s = 2.9 and  $3.4 \mu\text{M}$ , respectively). Similar to the 6-unsubstituted coumarins **10a-g**, it was noted that in the 6-bromocoumarin series, inclusion of other phenyl substituents (compounds **10h-n**) lowered the *hCA* IX inhibition constants showing  $K_i$ s in the range 6.2–18.2  $\mu\text{M}$ . Superiorly, the replacement of six-membered phenyl with five-membered 2-thienyl ring potentially elevated the inhibition constants for both 6-unsubstituted and 6-bromocoumarins (**11a** and **11c**;  $K_i$ s = 0.48 and 0.59  $\mu\text{M}$ , respectively) compared to their phenyl counterparts (**10a** and **10h**;  $K_i$ s = 0.82 and 0.93  $\mu\text{M}$ , respectively). Notably, utilising 2-furyl functionality in place of phenyl/thienyl group did not result in significant change in potency (**11b** and **11d**;  $K_i$ s = 0.79 and 0.91  $\mu\text{M}$ , respectively).


Collectively, the deduced SAR for *hCA* IX inhibition suggests that applying of unsubstituted thiazolidinedione (**5a-b**) is more favoured than their substituted analogues (**10a-n** and **11a-d**) affording the most potent *hCA* IX inhibitors in this study. Furthermore, the lack of substitution at 6-position of coumarin (**5a**, **10a-g** and **11a-b**) is more advantageous for such type of activity relative to 6-bromo counterparts (**5b**, **10h-n** and **11c-d**). Additionally, appending of unsubstituted phenyl ring (**10a**, **10h**) is the most beneficial pattern within all tested benzylidene counterparts (**10a-n**), while replacement of phenyl with 2-thienyl moiety gave the most potent *hCA* IX inhibitors (**11a** and **11c**) within all arylidene derivatives (**10a-n** and **11a-d**).

Finally, the inhibition profiles (Table 1) revealed that the cancer-related *hCA* XII isoform was inhibited by the coumarins **5a-b**, **10a-n** and **11a-d** displaying a range of inhibition constants from submicromolar level to low micromolar values ( $K_i$ s ranged from

0.15 to 10.4  $\mu\text{M}$ ). The unsubstituted thiazolidinedione-bearing coumarins **5a-b** emerged as the most effective *hCA* XII inhibitors, with submicromolar inhibition constants (**5a**;  $K_i = 0.15 \mu\text{M}$  and **5b**;  $K_i = 0.31 \mu\text{M}$ ).

It should be pointed out that bromination at 6-position of coumarin **5b** led to 2-fold diminished inhibition for *hCA* XII relative to the unsubstituted analogue **5a**, in a similar manner observed in the SAR for *hCA* IX inhibition, Table 1. Concerning the benzylidene derivatives **10a-n**, it was observed that appending a phenyl to thiazolidinedione moiety resulted in the most potent *hCA* XII inhibitors (at submicromolar level) within this series (**10a**;  $K_i = 0.75 \mu\text{M}$  and **10h**;  $K_i = 0.87 \mu\text{M}$ ). The incorporation of different substituents to the phenyl group reduced the inhibitory potential affording  $K_i$ s spanning between 2.3 and 10.4  $\mu\text{M}$ . Furthermore, the absence of substitution at 6-position of coumarin is beneficial for inhibition (**10a**;  $K_i = 0.75 \mu\text{M}$ ), whereas 6-bromination decreased the activity (**10h**;  $K_i = 0.87 \mu\text{M}$ ), Table 1. It was noted that replacement of the phenyl group (**10a**;  $K_i = 0.75 \mu\text{M}$  and **10h**;  $K_i = 0.87 \mu\text{M}$ ) with 2-thienyl or 2-furyl functionalities reduced  $K_i$ s for the 6-unsubstituted coumarins (**11a**;  $K_i = 0.83 \mu\text{M}$  and **11b**;  $K_i = 1.1 \mu\text{M}$ , respectively), while raised  $K_i$ s for the 6-bromocoumarins (**11c**;  $K_i = 0.44 \mu\text{M}$  and **11d**;  $K_i = 0.82 \mu\text{M}$ , respectively). This is unlike the pattern in *hCA* IX inhibition profile and points to a potential future avenue of exploration towards selectivity of *hCA* XII over *hCA* IX.

To summarise, the elicited SAR highlighted that unsubstituted thiazolidinedione derivatives (**5a-b**) exerted more superior potency relative to their substituted counterparts (**10a-n** and **11a-d**) resulting in the most potent *hCA* XII inhibitors in this work (**5a-b**). Moreover, within all benzylidene derivatives **10a-n**, the unsubstituted phenyl counterparts exerted the best inhibition

**Table 1.** Inhibition data for *h*CA I, II, IX and XII isoforms with 2,4-thiazolidinedione-tethered coumarins (**5a–b**, **10a–n** and **11a–d**) and AAZ.

Cmpd	R <sub>1</sub>	R <sub>2</sub>	K <sub>i</sub> (μM) <sup>a,b</sup>			
			CA I	CA II	CA IX	CA XII
<b>5a</b>	H	–	>100	>100	0.12	0.15
<b>5b</b>	Br	–	>100	>100	0.24	0.31
<b>10a</b>	H		>100	>100	0.82	0.75
<b>10b</b>	H		>100	>100	4.3	4.0
<b>10c</b>	H		>100	>100	5.8	4.5
<b>10d</b>	H		>100	>100	8.4	6.2
<b>10e</b>	H		>100	>100	12.3	8.0
<b>10f</b>	H		>100	>100	2.2	3.8
<b>10g</b>	H		>100	>100	2.3	4.1
<b>10h</b>	Br		>100	>100	0.93	0.87
<b>10i</b>	Br		>100	>100	6.2	2.3
<b>10j</b>	Br		>100	>100	8.9	4.9
<b>10k</b>	Br		>100	>100	16.4	6.6
<b>10l</b>	Br		>100	>100	18.2	10.4
<b>10m</b>	Br		>100	>100	2.9	3.2
<b>10n</b>	Br		>100	>100	3.4	2.8
<b>11a</b>	H		>100	>100	0.48	0.83
<b>11b</b>	H		>100	>100	0.79	1.1
<b>11c</b>	Br		>100	>100	0.59	0.44
<b>11d</b>	Br		>100	>100	0.91	0.82
<b>AAZ</b>	–	–	250	12.5	25.0	5.7

<sup>a</sup>Mean from 3 different assays, by a stopped flow technique (errors were in the range of ± 5–10% of the reported values); <sup>b</sup>incubation time of 6 h.

profiles (**10a** and **10h**), however the replacement of phenyl with 2-thienyl or 2-furyl along with 6-bromination at coumarin scaffold potentiated the inhibitory impact of compounds (**11c** and **11d**). Overall, the herein reported coumarins emerge as selective

inhibitors towards the tumour-related *h*CA IX and XII over the off-target *h*CA I and II that suggests their use as promising candidates for the development of more potent, selective *h*CA IX and XII inhibitors as anticancer agents.

### 3.3. Anticancer activity


#### 3.3.1. In vitro antiproliferative activity against MCF-7 breast cancer cell line

The antiproliferative action of the most potent and selective *hCA IX/XII* inhibitors **10a**, **10h** and **11a–d** was assessed against MCF-7 breast cancer cell line, since the overexpression of *hCA IX* is well-reported to be associated with poor prognosis of breast cancer [37] and the cell line has been previously used as a model in CA medicinal chemistry investigations. The antiproliferative potential was investigated using MTT assay [38] under hypoxic conditions employing staurosporine as a reference anticancer drug. The results are presented in Table 2 as median inhibitory concentration ( $IC_{50}$ ) which denotes the concentration of the tested drug


**Table 2.** Anti-proliferative activities of 2,4-thiazolidinedione-tethered coumarins **10a**, **10h** and **11a–c** against MCF-7 cell line.

Compound	$IC_{50}$ ( $\mu M$ ) <sup>a</sup> (MCF-7)
<b>10a</b>	3.13 ± 0.18
<b>10h</b>	11.1 ± 0.65
<b>11a</b>	0.48 ± 0.03
<b>11b</b>	4.14 ± 0.24
<b>11c</b>	9.56 ± 0.56
<b>11d</b>	1.65 ± 0.1
Staurosporine	2.44 ± 0.14

<sup>a</sup> $IC_{50}$  values are the mean ± SD of three experiments.



**Figure 2.** Impact of the tested coumarin **11a** on the progression of cell cycle of MCF-7 cells.



**Figure 3.** Effect of coumarin **11a** on the percentage of AV positive staining in breast MCF-7 cells.

required to produce 50% growth inhibition of the cancer cell compared to the negative control.

Investigation of the antiproliferative effects towards MCF-7 breast cancer cell line confirmed that the tested coumarins **10a**, **10h** and **11a–c** exhibited moderate to excellent growth inhibitory influence ( $IC_{50}$  ranged between 0.48 and 11.1  $\mu M$ ). Of special interest, the 2-thienyl-bearing 6-unsubstituted coumarin **11a**, that displayed potent *hCA IX/XII* inhibition at submicromolar level, exerted excellent antiproliferative action at submicromolar value ( $IC_{50}$  equals 0.48  $\mu M$ ). Likewise, the other tested coumarins **10a**, **10h**, **11b–d** demonstrated moderate growth inhibitory action with  $IC_{50}$  values equal 3.13, 11.1, 4.14, 9.56 and 1.65  $\mu M$ , respectively compared to staurosporine as reference drug ( $IC_{50}$  = 2.44  $\mu M$ ), Table 2.

#### 3.3.2. Cell cycle analysis

The influence of 2-thienyl-bearing 6-unsubstituted coumarin **11a** on the cell cycle progression was investigated by flow cytometric in MCF-7 breast cancer cells, at 24h following treatment at its  $IC_{50}$  value (0.48 ± 0.03  $\mu M$ ), Figure 2.

As illustrated in Figure 2, the flow cytometric results showed that the exposure of MCF-7 breast cancer cells to compound **11a** gave rise to a significant rise in the cell populations at Sub- $G_1$ , which increased by 19.7 folds with concomitant decrease in  $G_2$ -M phase by 2.6 folds compared to the control, in addition to decline in cell populations within S and  $G_0$ - $G_1$  phases. This observation strongly suggests coumarin **11a** induces apoptosis in MCF-7 cells.

#### 3.3.3. Annexin V-FITC/propidium iodide (AV/PI) apoptosis assay

Annexin V-FITC/propidium iodide (AnxV/PI) dual staining assay was employed to confirm the potential apoptotic impact of coumarin **11a** on early and late apoptosis percentages in MCF-7 breast cancer cells (Figure 3 and Table 3). This flow cytometric analysis highlighted that compound **11a** was able to induce apoptosis in MCF-7 cells as indicated by the significant elevation in the percentage of annexin V-FITC-stained apoptotic cells including early apoptosis (Figure 3, lower right) from 0.37 to 4.23% and late apoptosis, Figure 3, upper right) from 0.15 to 25.7%. This represents 57 folds total increase relative to the control in apoptotic cells.

**Table 3.** Distribution of AV-FITC/PI positive stained apoptotic MCF-7 cells.

Comp.	Apoptosis			Necrosis
	Total	Early	Late	
<b>11a</b>	29.93	4.23	25.7	17.39
Control	0.52	0.37	0.15	1.14

#### 4. Conclusions

In this study, different 2,4-thiazolidinedione-tethered coumarins **5a–b**, **10a–n** and **11a–d** have been synthesised and evaluated for their inhibitory action against the cancer-associated *h*CA IX and XII, in addition to the physiologically dominant *h*CA I and II, in order to explore their selectivity. Interestingly, none of the coumarins had any inhibitory effect on off-target *h*CA I and II isoforms. Unsubstituted phenyl-bearing coumarins **10a**, **10h**, and 2-thienyl/furyl-bearing coumarins **11a–c** exhibited the best *h*CA IX ( $K_s$  between 0.48 and 0.93  $\mu$ M) and *h*CA XII ( $K_s$  between 0.44 and 1.1  $\mu$ M) inhibitory actions. Coumarins **10a**, **10h** and **11a–c** were subjected to an *in vitro* antiproliferative assay, and then the most potent antiproliferative agent **11a** was tested to explore its impact on the cell cycle phases and apoptosis in MCF-7 breast cancer cells furnishing more insights on the potential anticancer activity of such compounds.

#### Disclosure statement

No potential conflict of interest was reported by the author(s). CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

#### Funding

This work was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, through the Research Groups Program Grant no [RGP-1440 – 0025](2). The work was also financed by the Italian Ministry for Education and Science (MIUR), grant PRIN: rot. 2017XYBP2R, and by Ente Cassa di Risparmio di Firenze (ECRF), grant [CRF2020.1395] to CTS.

#### ORCID

Alessio Nocentini  <http://orcid.org/0000-0003-3342-702X>  
 Claudiu T. Supuran  <http://orcid.org/0000-0003-4262-0323>

#### References

- (a) Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32. (b) Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. *J Exp Pharmacol* 2020;12:603–17.
- (a) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2017;12:61–88; (b) Supuran CT. Emerging role of carbonic anhydrase inhibitors. *Clin Sci* 2021;135:1233–49.
- (a) Supuran CT, How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016;31:345–60. (b) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. *J Enzyme Inhib Med Chem* 2021;36:561–80.
- (a) Supuran CT, Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81. (b) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011;10:767–77.
- (a) Supuran CT. Carbonic anhydrases-an overview. *Curr Pharm Des* 2008;14:603–14. (b) Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. *Metabolites* 2020;10:412.(c) Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. *Bioorg Med Chem Lett* 2004;14:869–73.
- (a) Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). *Expert Opin Ther Pat* 2013;23:681–91. (b) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. *Expert Opin Ther Pat* 2018;28:709–12.
- Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. *Expert Opin Drug Discov* 2021;16:1209–25.
- Narella SG, Shaik MG, Mohammed A, et al. Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors. *Bioorg Chem* 2019;87:765–72.
- (a) Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. *Expert Opin Investig Drugs* 2022;in press.(b) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. *Expert Opin Investig Drugs* 2018;27:963–70.
- (a) Thacker PS, Alvala M, Arifuddin M, et al. Design, synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors. *Bioorg Chem* 2019;86:386–92. (b) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. *Metabolites* 2017;7:48.
- (a) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). *Expert Opin Ther Pat* 2018;28:729–40. (b) Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. *Sci Adv* 2021;7:eabj0364.(c) McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. *Am J Clin Oncol* 2020;43:484–90.
- (a)Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68. (b) Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. *Med Res Rev* 2018;38:1799–836.

13. (a) Eldehna WM, Abdelrahman MA, Nocentini A, et al. Synthesis, biological evaluation and *in silico* studies with 4-benzylidene-2-phenyl-5(4H)-imidazolone-based benzenesulfonamides as novel selective carbonic anhydrase IX inhibitors endowed with anticancer activity. *Bioorg Chem* 2019;90:103102. (b) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. *Eur J Med Chem* 1996;31:1001–10.
14. Shaldam M, Eldehna WM, Nocentini A, et al. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. *Eur J Med Chem* 2021;216:113283.
15. Abdelrahman MA, Eldehna WM, Nocentini A, et al. Novel benzofuran-based sulphonamides as selective carbonic anhydrases IX and XII inhibitors: synthesis and *in vitro* biological evaluation. *J Enzyme Inhib Med Chem* 2020;35:298–305.
16. Abdelrahman MA, Ibrahim HS, Nocentini A, et al. Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: synthesis, biological and molecular dynamics analysis. *Eur J Med Chem* 2021;209:112897.
17. Chandak N, Ceruso M, Supuran CT, Sharma PK. Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII. *Bioorganic Med Chem* 2016;24:2882–6.
18. (a) Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. *J Enzyme Inhib Med Chem* 2020;35:1462–70. (b) Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. *J Enzyme Inhib Med Chem* 2021;36:1702–14.
19. Al-Warhi T, Sabt A, Elkaeed EB, Eldehna WM. Recent advancements of coumarin-based anticancer agents: an up-to-date review. *Bioorg Chem* 2020;103:104163.
20. Garg SS, Gupta J, Sharma S, Sahu D. An insight into the therapeutic applications of coumarin compounds and their mechanisms of action. *Eur J Pharm Sci* 2020;152:105424.
21. (a) Maresca A, Scozzafava A, Supuran CT. 7, 8-Disubstituted-but not 6, 7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. *Bioorg Med Chem Lett* 2010;20:7255–8. (b) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? *Med Res Rev* 2020;40:2485–565.
22. Nocentini A, Carta F, Ceruso M, et al. Click-tailed coumarins with potent and selective inhibitory action against the tumor-associated carbonic anhydrases IX and XII. *Bioorg Med Chem* 2015;23:6955–66.
23. (a) Bozdogan M, Alafeefy AM, Altamimi AM, et al. Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity. *Bioorg Med Chem* 2017;25:677–83. (b) Krasavin M, Kalinin S, Sharonova T, Supuran CT. Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. *J Enzyme Inhib Med Chem* 2020;35:1555–61. (c) Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. *Bioorg Med Chem Lett* 2010;20:5050–3.
24. (a) Carta F, Maresca A, Scozzafava A, Supuran CT. Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII. *Bioorg Med Chem* 2012;20:2266–73. (b) Dar'ın D, Kantin G, Kalinin S, et al. Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide – a new caspase-activating proapoptotic agent. *Eur J Med Chem* 2021;222:113589.
25. Koelsch CF. Bromination of 3-acetocoumarin. *J Am Chem Soc* 1950;72:2993–5.
26. Ben Mohamed S, Rachedi Y, Hamdi M, et al. An efficient synthetic access to substituted thiazolyl-pyrazolyl-chromene-2-ones from dehydroacetic acid and coumarin derivatives by a multicomponent approach. *Eur J Org Chem* 2016;2016:2628–36.
27. Valadbeigi E, Ghodsi S. Synthesis and characterization of some new thiazolidinedione derivatives containing a coumarin moiety for their antibacterial and antifungal activities. *Med Chem* 2017;07:178–85.
28. Mishra G, Sachan N, Chawla P. Synthesis and evaluation of thiazolidinedione-coumarin adducts as antidiabetic, anti-inflammatory and antioxidant agents. *Lett Org Chem* 2015;12:429–55.
29. Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. *Eur J Med Chem* 2019;162:147–60.
30. Eldehna WM, Nocentini A, Elsayed ZM, et al. Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer. *ACS Med Chem Lett* 2020;11:1022–7.
31. Elbadawi MM, Eldehna WM, Nocentini A, et al. Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. *Eur J Med Chem* 2021;218:113360.
32. Sabt A, Eldehna WM, Al-Warhi T, et al. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and *in silico* insights. *J Enzyme Inhib Med Chem* 2020;35:1616–30.
33. Al-Rashood ST, Hamed AR, Hassan GS, et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. *J Enzyme Inhib Med Chem* 2020;35:831–9.
34. Eissa IH, El-Helby AG, Mahdy HA, et al. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: design, synthesis, and anti-proliferative evaluation. *Bioorg Chem* 2020;105:104380.
35. El-Helby AG, Sakr H, Ayyad RR, et al. Design, synthesis, molecular modeling, *in vivo* studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. *Bioorg Chem* 2020;103:104233.
36. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971;246:2561–73.

37. (a) Hedlund EE, McDonald PC, Nemirovsky O, et al. Harnessing induced essentiality: targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts. *Cancers* 2019;11:1002. (b) Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. *J Med Chem* 2012;55:5591–600.
38. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983;65:55–63.